Text Size

Long-Term Behavior Change - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2008 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Friends Research Institute, Inc.
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00158197
First received: September 8, 2005
Last updated: May 23, 2008
Last verified: May 2008
History of Changes
  Purpose

The purpose of this study is to determine if different reinforcement procedures (i.e., schedules) produce different patterns of long-term abstinence from methamphetamine. We anticipate that the three contingency management conditions will promote longer periods of abstinence in the year following treatment relative to the standard control group. Furthermore, we predict that the intermittent reinforcement procedures will produce longer periods of continued abstinence (i.e., long-term behavior change) in the year following treatment than the continuous reinforcement procedure. Finally, we predict that the intermittent unpredictable schedule will produce longer lasting behavior change than the intermittent predictable schedule. Methamphetamine use will be measured using urine toxicology and self-report of methamphetamine use.


Condition Intervention
Adherence
Amphetamine-Related Disorders
Behavior Therapy
Contingency Management
Drug Counseling
Health Behaviors
Methamphetamine
Sexual Risk Behaviors
Substance Dependence
 Behavioral: Contingency management

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Behavior Change: Reinforcement Schedule Effects

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Methamphetamine Use during and following intervention

Estimated Enrollment: 120
Study Start Date: December 2004
Detailed Description:

Briefly the four study conditions are: (1) standard treatment which consists of 16 weeks of psychosocial treatment, (2) continuous contingency management which consists of 16 weeks of psychosocial treatment with a contingency management procedure in effect during the first twelve weeks in which vouchers are made available after each provision of a methamphetamine-negative urine test, (3) intermittent predictable contingency management which consists of 16 weeks of psychosocial treatment with a contingency management procedure in effect during the first twelve weeks in which vouchers are available after the provision of every three consecutive methamphetamine-negative urine samples, and (4) intermittent unpredictable contingency management which consists of 16 weeks of psychosocial treatment with a contingency management procedure in effect during the first twelve weeks in which vouchers are available on one day each week (randomly selected after the first week) for the provision of methamphetamine-negative urine samples provided all urine samples since delivery of the last reinforcer were also methamphetamine negative.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meet DSM-IV criteria for methamphetamine dependence
  • Willing and able to comply with study procedures
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Have a medical condition that, in the study PI's judgment, might interfere with safe study participation
  • Have a recent (past 30 days) history of suicide attempts and/or current serious suicidal intention or plan as assessed by the BDI
  • Have a history of violent criminal behavior or be on parole
  • Any other circumstances that, in the opinion of the PI, would interfere with safe study participation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00158197

Contacts
Contact: Joy E Chudzynski, B.A., M.A. (310)479-9330 joychud@friendsresearch.org

Locations
United States, California
Friends Research Institute Recruiting
Los Angeles, California, United States, 90025
Contact: Joy E Chudzynski, B.A., M.A.     310-479-9330     joychud@friendsresearch.org    
Friends Research Institute Not yet recruiting
Rancho Cucamonga, California, United States, 91730
Contact: Joy E Chudzynski, B.A., M.A.     310-479-9330     joychud@friendsresearch.org    
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Friends Research Institute, Inc.
Investigators
Principal Investigator: John Roll, Ph.D. University of California, Los Angeles
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00158197     History of Changes
Other Study ID Numbers: NIDA-17407-1, R01-17407-1
Study First Received: September 8, 2005
Last Updated: May 23, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Amphetamine-Related Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 22, 2013